Shukra Pharmaceuticals (524632) Q3 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 25/26 earnings summary
4 Feb, 2026Executive summary
Board approved unaudited financial results for Q3 and nine months ended December 31, 2025, and re-appointed the Managing Director for a five-year term.
Statutory auditors provided an unqualified review opinion on both standalone and consolidated results.
Financial highlights
Q3 FY26 consolidated revenue from operations was ₹3,913.48 lakhs, up from ₹1,058.43 lakhs in Q3 FY25.
Net profit for Q3 FY26 stood at ₹2,036.46 lakhs, compared to ₹316.44 lakhs in Q3 FY25.
For the nine months ended December 31, 2025, total income was ₹5,404.09 lakhs and net profit was ₹2,377.46 lakhs.
Basic and diluted EPS for Q3 FY26 was ₹0.47, up from ₹0.72 in Q3 FY25.
Outlook and guidance
Board reviewed ongoing business and confirmed continued focus on operational excellence and growth.
Latest events from Shukra Pharmaceuticals
- Sales and exports surged, but higher depreciation cut profit as injectable expansion advanced.524632
Q4 96/97 - Sales grew 18%, profit rose, and injectable production was poised to begin amid operating cash outflow.524632Q4 97/98
- Sales and exports surged as expansion funding coincided with negative operating cash flow.524632Q4 99/00
- Turnover rose 22.72%; injection-plant launch awaited regulatory approval.524632Q4 98/99
- Higher sales, lower PAT after a ₹5.65m write-off, and restructuring define FY16.524632Q4 15/16
- Revenue surged, but profit collapsed amid qualified audit and compliance concerns.524632Q4 19/20
- Revenue and profit surged; net debt turned negative and a ₹1 dividend was proposed.524632Q4 23/24
- FY23 earnings surged as export growth advanced alongside higher receivables and tax exposure.524632Q4 22/23
- A bank settlement lifted FY12 profit despite declining revenue and restructuring pressures.524632Q4 11/12
- Revenue declined, losses deepened, and restructuring remained central to the outlook.524632Q4 12/13